Article

ADAM12 Produced by Tumor Cells Rather than Stromal Cells Accelerates Breast Tumor Progression

Department of Biomedical Sciences and Biotech Research & Innovation Centre, University of Copenhagen, Ole Maaløes Vej 5, 2200 Copenhagen N, Denmark.
Molecular Cancer Research (Impact Factor: 4.5). 08/2011; 9(11):1449-61. DOI: 10.1158/1541-7786.MCR-11-0100
Source: PubMed

ABSTRACT Expression of ADAM12 is low in most normal tissues but is markedly increased in numerous human cancers, including breast carcinomas. We have previously shown that overexpression of ADAM12 accelerates tumor progression in a mouse model of breast cancer (PyMT). In this study, we found that ADAM12 deficiency reduces breast tumor progression in the PyMT model. However, the catalytic activity of ADAM12 seems to be dispensable for its tumor-promoting effect. Interestingly, we show that ADAM12 endogenously expressed in tumor-associated stroma in the PyMT model does not influence tumor progression, but that ADAM12 expression by tumor cells is necessary for tumor progression in these mice. This finding is consistent with our observation that in human breast carcinoma, ADAM12 is almost exclusively located in tumor cells and, only rarely, seen in the tumor-associated stroma. We hypothesized, however, that the tumor-associated stroma may stimulate ADAM12 expression in tumor cells, on the basis of the fact that TGF-β1 stimulates ADAM12 expression and is a well-known growth factor released from tumor-associated stroma. TGF-β1 stimulation of ADAM12-negative Lewis lung tumor cells induced ADAM12 synthesis, and growth of these cells in vivo induced more than 200-fold increase in ADAM12 expression. Our observation that ADAM12 expression is significantly higher in the terminal duct lobular units (TDLU) adjacent to human breast carcinoma compared with TDLUs found in normal breast tissue supports our hypothesis that tumor-associated stroma triggers ADAM12 expression.

Download full-text

Full-text

Available from: Atsuko Sehara-Fujisawa, Jun 27, 2015
0 Followers
 · 
207 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A recently identified breast cancer-associated mutation in the metalloprotease ADAM12 alters a potential dileucine trafficking signal, which could affect protein processing and cellular localization. ADAM12 belongs to the group of A Disintegrin And Metalloproteases (ADAMs), which are typically membrane-associated proteins involved in ectodomain shedding, cell-adhesion, and signaling. ADAM12 as well as several members of the ADAM family are over-expressed in various cancers, correlating with disease stage. Three breast cancer-associated somatic mutations were previously identified in ADAM12, and two of these, one in the metalloprotease domain and another in the disintegrin domain, were investigated and found to result in protein misfolding, retention in the secretory pathway, and failure of zymogen maturation. The third mutation, p.L792F in the ADAM12 cytoplasmic tail, was not investigated, but is potentially significant given its location within a di-leucine motif, which is recognized as a potential cellular trafficking signal. The present study was motivated both by the potential relevance of this documented mutation to cancer, as well as for determining the role of the di-leucine motif in ADAM12 trafficking. Expression of ADAM12 p.L792F in mammalian cells demonstrated quantitatively similar expression levels and zymogen maturation as wild-type (WT) ADAM12, as well as comparable cellular localizations. A cell surface biotinylation assay demonstrated that cell surface levels of ADAM12 WT and ADAM12 p.L792F were similar and that internalization of the mutant occurred at the same rate and extent as for ADAM12 WT. Moreover, functional analysis revealed no differences in cell proliferation or ectodomain shedding of epidermal growth factor (EGF), a known ADAM12 substrate between WT and mutant ADAM12. These data suggest that the ADAM12 p.L792F mutation is unlikely to be a driver (cancer causing)-mutation in breast cancer.
    PLoS ONE 05/2012; 7(5):e37628. DOI:10.1371/journal.pone.0037628 · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Based on its shedding and binding activities, the disintegrin and metalloprotease 12 (ADAM12) has been implicated in cell signaling. Here we investigate the intracellular protein interaction network of the transmembrane ADAM12L variant using an integrative approach. We identify the integrin-linked kinase (ILK) as a new partner for ADAM12L cellular functions. We demonstrate that ADAM12L coimmunoprecipitates with ILK in cells and that its cytoplasmic tail is required for this interaction. In human cultured hepatic stellate cells (HSCs), which express high levels of endogenous ADAM12L and ILK, the two proteins are redistributed to focal adhesions upon stimulation of a β1 integrin-dependent pathway. We show that down-regulation of ADAM12L in HSCs leads to cytoskeletal disorganization and loss of adhesion. Conversely, up-regulation of ADAM12L induces the Akt Ser-473 phosphorylation-dependent survival pathway via stimulation of β1 integrins and activation of phosphoinositide 3-kinase (PI3K). Depletion of ILK inhibits this effect, which is independent of ADAM12L proteolytic activity and involves its cytoplasmic domain. We further demonstrate that overexpression of ADAM12L promotes kinase activity from ILK immunoprecipitates. Our data suggest a new role for ADAM12L in mediating the functional association of ILK with β1 integrin to regulate cell adhesion/survival through a PI3K/Akt signaling pathway.
    Molecular biology of the cell 07/2012; 23(17):3461-72. DOI:10.1091/mbc.E11-11-0918 · 5.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: L’ADAM12 « A Desintegrin And Metalloprotease 12 » est une métalloprotéase impliquée dans la croissance et les interactions cellulaires. Produite par le placenta dès le début de la grossesse, elle favorise le développement fœtal. Récemment, une surexpression d’ADAM12 a été décrite dans certains cancers. Enzyme à plusieurs domaines intramembranaires, elle possède, d’une part, une activité protéolytique (shedding) sur de nombreux substrats (IGFBP et HB-EGF…) qui lui donne un rôle dans la croissance et l’hypertrophie cellulaire. D’autre part, son activité désintégrine lui confère un rôle dans l’apoptose, la différenciation et l’organogenèse. Des techniques automatisées de dosage de l’ADAM12 sur sérum, se sont développées pour étudier l’avantage de ce marqueur, en association avec les autres marqueurs sériques, dans le cadre du dépistage prénatal de la trisomie 21 fœtale ou comme marqueur d’aneuploïdies ou de pré-éclampsie. Les premiers résultats et les performances observées (variabilité des anticorps et des effectifs étudiés) nécessitent des confirmations sur de plus amples cohortes. L’ADAM12 semble impliquée également dans des processus pathologiques en cancérologie mais aussi dans des désordres musculosquelettiques, cardiaques ou neurologiques. Enfin, des perspectives thérapeutiques basées sur l’inhibition d’ADAM12 ont été proposées en cardiologie et en cancérologie.
    Immuno-analyse & Biologie Spécialisée 08/2012; 27(4):195–204. DOI:10.1016/j.immbio.2012.02.010 · 0.11 Impact Factor